CLINICAL TRIAL SUMMARY

MDACC Study No:2012-0334 (clinicaltrials.gov NCT No: NCT01624805)
Title:Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisone, and GCSF (Filgrastim or Pegfilgrastim) in Patients with Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
Principal Investigator:Tapan Kadia
Treatment Agent:Antithymocyte Globulin; CYCLOSPORIN A; G-CSF; Pegfilgrastim
Study Status:Open
Study Description:The goal of this clinical research study is to learn if horse anti-thymocyte
globulin
(hATG), given in combination with methylprednisolone, cyclosporine, and G-CSF
(filgrastim or pegfilgrastim), can help to control MM and/or low-int-1 risk
MDS. The safety of this drug combination will also be studied.

hATG is made from horse blood and targets immune cells known as T-lymphocytes.
Since T-lymphocytes are believed to be involved in causing low blood counts in
AA and in some cases of MDS, killing these cells may help treat the disease.

Methylprednisolone and cyclosporine work to suppress immune cells called
lymphocytes. This may help to improve low blood counts in AA and in some cases
of MDS.

Filgrastim and pegfilgrastim are designed to cause white blood cells to grow.
This may help to fight infections and help improve the white blood cell count.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Antithymocyte Globulin
CYCLOSPORIN A
G-CSF
Pegfilgrastim
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Tapan Kadia
Dept:Leukemia
For Clinical Trial Enrollment:713-563-3534
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults